Loading clinical trials...
Loading clinical trials...
Determination of the Absolute Bioavailability of GSK1120212 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microdose of GSK1120212 in Subjects With Solid Tumors
Conditions
Interventions
GSK1120212
GSK1120212B
Locations
1
United States
GSK Investigational Site
Tacoma, Washington, United States
Start Date
June 20, 2011
Primary Completion Date
December 17, 2011
Completion Date
December 17, 2011
Last Updated
November 13, 2017
NCT05372640
NCT05053971
NCT03191149
NCT04235764
NCT04929028
NCT05884320
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions